

BIOTIME INC  
Form 4  
June 06, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KINGSLEY ALFRED D**

(Last) (First) (Middle)  
150 E. 57TH STREET  
(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIOTIME INC [BTX]**

3. Date of Earliest Transaction (Month/Day/Year)  
06/04/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

See Remarks

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, no par value	06/04/2013		S		320,000	D	<u>(1)</u>
Common Shares, no par value					1,682,505	I	By Greenbelt Corp.
Common Shares, no par value					375,351	I	By Greenway Partners, LP

Edgar Filing: BIOTIME INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Shares	\$ 5	06/04/2013		S	80,000	06/04/2013	06/04/2018	Common Shares	80,000
Option to Purchase Common Shares	\$ 4.6					<u>(3)</u>	06/30/2017	Common Shares	50,000
Option to Purchase Common Shares	\$ 5.13					<u>(4)</u>	06/30/2016	Common Shares	50,000
Option to Purchase Common Shares	\$ 5.45					<u>(5)</u>	08/09/2015	Common Shares	50,000
Option to Purchase Common Shares	\$ 2.3					<u>(6)</u>	07/01/2014	Common Shares	50,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KINGSLEY ALFRED D 150 E. 57TH STREET	X	X	See Remarks	

NEW YORK, NY 10022

## Signatures

/s/ Alfred D.  
Kingsley

06/06/2013

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On June 4, 2013, Mr. Kingsley sold 320,000 BioTime common shares and 80,000 options to purchase 80,000 common shares in two private transactions. Each common share and one quarter of each option were sold for an aggregate price of \$4.155.
  - (2) Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.  
12,500 options became exercisable on September 30, 2012; 12,500 options became exercisable on December 31, 2012; 12,500 options
  - (3) became exercisable on March 31, 2013; and the remaining 12,500 options will become exercisable on June 30, 2013 based upon continued service on the board of directors.
  - (4) 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.
  - (5) 12,500 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.
  - (6) 12,500 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.

### Remarks:

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.